76 related articles for article (PubMed ID: 1769697)
21. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production.
Ding AH; Nathan CF; Stuehr DJ
J Immunol; 1988 Oct; 141(7):2407-12. PubMed ID: 3139757
[TBL] [Abstract][Full Text] [Related]
22. Effect of tumour growth on the macrophage response to the antitumour agent 5,6-dimethylxanthenone-4-acetic acid.
Ching LM; Joseph WR; Baguley BC
Anticancer Res; 1993; 13(6A):2069-75. PubMed ID: 8297115
[TBL] [Abstract][Full Text] [Related]
23. IL-10 inhibits cytokine production by activated macrophages.
Fiorentino DF; Zlotnik A; Mosmann TR; Howard M; O'Garra A
J Immunol; 1991 Dec; 147(11):3815-22. PubMed ID: 1940369
[TBL] [Abstract][Full Text] [Related]
24. IFN-gamma and LPS overcome glucocorticoid inhibition of priming for superoxide release in human monocytes. Evidence that secretion of IL-1 and tumor necrosis factor-alpha is not essential for monocyte priming.
Szefler SJ; Norton CE; Ball B; Gross JM; Aida Y; Pabst MJ
J Immunol; 1989 Jun; 142(11):3985-92. PubMed ID: 2541203
[TBL] [Abstract][Full Text] [Related]
25. Transforming growth factor-beta 1 primes macrophages for enhanced expression of the nitric oxide synthase gene for nitric oxide-dependent cytotoxicity against Entamoeba histolytica.
Lin JY; Seguin R; Keller K; Chadee K
Immunology; 1995 Jul; 85(3):400-7. PubMed ID: 7558128
[TBL] [Abstract][Full Text] [Related]
26. Macrophage activation by granulocyte/macrophage colony-stimulating factor. Priming for enhanced release of tumor necrosis factor-alpha and prostaglandin E2.
Heidenreich S; Gong JH; Schmidt A; Nain M; Gemsa D
J Immunol; 1989 Aug; 143(4):1198-205. PubMed ID: 2473121
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of macrophage tumoricidal activity by glucocorticoids.
Hogan MM; Vogel SN
J Immunol; 1988 Jan; 140(2):513-9. PubMed ID: 3121748
[TBL] [Abstract][Full Text] [Related]
28. The activation of tumoricidal properties in macrophages of endotoxin responder and nonresponder mice by liposome-encapsulated immunomodulators.
Fogler WE; Talmadge JE; Fidler IJ
J Reticuloendothel Soc; 1983 Mar; 33(3):165-74. PubMed ID: 6834360
[TBL] [Abstract][Full Text] [Related]
29. Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-gamma, IL-4, IL-6, or TNF-alpha.
Nishihara K; Barth RF; Wilkie N; Lang JC; Oda Y; Kikuchi H; Everson MP; Lotze MT
Cancer Gene Ther; 1995 Jun; 2(2):113-24. PubMed ID: 7621259
[TBL] [Abstract][Full Text] [Related]
30. Neuroprotective effects of cyclooxygenase-2 inhibitor celecoxib against toxicity of LPS-stimulated macrophages toward motor neurons.
Huang Y; Liu J; Wang LZ; Zhang WY; Zhu XZ
Acta Pharmacol Sin; 2005 Aug; 26(8):952-8. PubMed ID: 16038627
[TBL] [Abstract][Full Text] [Related]
31. [In vitro activation of immune cells by a mycolic acid-containing glycolipid, trehalose-2,3,6'-trimycolate, derived from Gordona aurantiaca].
Ohtsubo Y; Furukawa M; Sugimoto N; Ikutoh M; Katoh Y; Yano I; Shinka S; Dohi Y
Nihon Saikingaku Zasshi; 1989 Nov; 44(6):797-803. PubMed ID: 2533624
[TBL] [Abstract][Full Text] [Related]
32. Induction of interferons (IFNs) and tumor necrosis factor (TNF) in mice by a novel glycolipid trehalose 2,3,6'-trimycolate from Rhodococcus aurantiacus (Gordona aurantiaca).
Fujita T; Sugimoto N; Yokoi F; Ohtsubo Y; Ikutoh M; Kato Y; Natsuhara Y; Oka S; Yano I
Microbiol Immunol; 1990; 34(6):523-32. PubMed ID: 1699114
[TBL] [Abstract][Full Text] [Related]
33. [An immune adjuvant activity of mycolic acid-containing glycolipid, trehalose-2,3,6'-trimycolate, derived from Gordona aurantiaca].
Ohtsubo Y; Furukawa M; Fujinobu Y; Sugimoto N; Ikutoh M; Katoh Y; Yano I; Higasa M; Shinka S; Dohi Y
Nihon Saikingaku Zasshi; 1989 Mar; 44(2):533-9. PubMed ID: 2788754
[TBL] [Abstract][Full Text] [Related]
34. [Granuloma formation in mice by liposomes of new glycolipid containing mycolic acids, "trehalose 2,3,6'-trimycolate"].
Yokoi F; Sugimoto N; Kato K; Kaneda K; Oka S; Yano I
Yakugaku Zasshi; 1989 Jan; 109(1):46-51. PubMed ID: 2732903
[TBL] [Abstract][Full Text] [Related]
35. Endogenous gamma interferon is essential in granuloma formation induced by glycolipid-containing mycolic acid in mice.
Asano M; Nakane A; Minagawa T
Infect Immun; 1993 Jul; 61(7):2872-8. PubMed ID: 8514390
[TBL] [Abstract][Full Text] [Related]
36. Optimal regimes for local IL-2 tumour therapy.
Den Otter W; De Groot JW; Bernsen MR; Heintz AP; Maas R; Hordijk GJ; Hill FW; Klein WR; Ruitenberg EJ; Rutten VP
Int J Cancer; 1996 May; 66(3):400-3. PubMed ID: 8621264
[TBL] [Abstract][Full Text] [Related]
37. [Protective effect of glycolipid containing mycolic acid derived from Gordona aurantiaca against Yersinia enterocolitica].
Fujita T; Kawata Y; Kitamura F; Sugimoto N; Yano I; Sawai H; Kato Y; Miyama A
Kansenshogaku Zasshi; 1988 Jan; 62(1):26-31. PubMed ID: 3137281
[No Abstract] [Full Text] [Related]
38. Activation of mouse peritoneal macrophages by synthetic glyceroglycolipid liposomes.
Naito M; Kudo I; Mukai-Sato Y; Tsushima S; Nomura H; Nojima S; Inoue K
Cancer Immunol Immunother; 1987; 24(2):158-64. PubMed ID: 3829050
[TBL] [Abstract][Full Text] [Related]
39. Granuloma formation and hemopoiesis induced by C36-48-mycolic acid-containing glycolipids from Nocardia rubra.
Kaneda K; Sumi Y; Kurano F; Kato Y; Yano I
Infect Immun; 1986 Dec; 54(3):869-75. PubMed ID: 3781628
[TBL] [Abstract][Full Text] [Related]
40. The evolution of independence from specific growth stimulation and inhibition in mammalian tumour-cell populations.
KLEIN G; KLEIN E
Symp Soc Exp Biol; 1957; 11():305-28. PubMed ID: 13486477
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
